In the current study, we aim to explore the occurrence and presentation level of anti-PDLIM1 autoantibodies in the sera of patients with ovarian cancer and further to evaluate its potential as a biomarker for the detection of OC. This evidence concerns the gene PDLIM1 and ovarian cancer.